Three years ago Caterpillar opted not to follow competitors down the conventional research path and instead gambled on a new technology it believed would be more efficient.

FORBES: GET LEAN

Pharmaceutical companies say that high monopoly rents on new medicines assure incentives for high-risk research on future path-breaking medicines and pay for past efforts that resulted in failure.

ECONOMIST: Sachs and drugs

Economic research has shown that the path to prosperity is not money creation but getting the institutions right, and thus getting prices right.

FORBES: Bernanke Administers Another Cruel Dose Of Financial Morphine With QE3